{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Synthesize Responses from the Retrieved Contexts"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 0: Environment Setup"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The .env file has been loaded\n"
     ]
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "from langchain_neo4j import Neo4jGraph\n",
    "from libs import create_vector_index, get_entities,embed_entity, vector_search,enhanced_chunk_finder\n",
    "import pandas as pd\n",
    "from conn import connect2Googlesheet\n",
    "from openai import OpenAI\n",
    "from synthlibs import graph_retriever, parse_relationships, final_context_builder,synthesize_response\n",
    "\n",
    "# plot figures in high resolution\n",
    "%config InlineBackend.figure_format = 'retina'\n",
    "# Force reload of the .env file\n",
    "try:\n",
    "    load_dotenv()\n",
    "    print(\"The .env file has been loaded\")\n",
    "except Exception as e:\n",
    "    print(\"The .env file has not been loaded. Reported error: \", e)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Connected to Neo4j database successfully.\n",
      "The 'entities' index already exists.\n"
     ]
    }
   ],
   "source": [
    "# Connect to Neo4j database\n",
    "try:\n",
    "    graph = Neo4jGraph(\n",
    "        url=os.getenv(\"NEO4J_URL\"),\n",
    "        username=os.getenv(\"NEO4J_USERNAME\"),\n",
    "        password=os.getenv(\"NEO4J_PASSWORD\"),\n",
    "    )\n",
    "    print(\"Connected to Neo4j database successfully.\")\n",
    "except ValueError as e:\n",
    "    print(f\"Could not connect to Neo4j database: {e}\")\n",
    "\n",
    "# Check if the entities index exists\n",
    "index_name = \"entities\"\n",
    "query = \"SHOW INDEXES YIELD name, type WHERE type = 'VECTOR' AND name = $index_name\"\n",
    "\n",
    "result = graph.query(query, params={\"index_name\": index_name})\n",
    "if result:\n",
    "    print(\"The 'entities' index already exists.\")\n",
    "else:\n",
    "    create_vector_index(graph, \"entities\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 1: Connect to Google Sheet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>condition</th>\n",
       "      <th>number</th>\n",
       "      <th>docs</th>\n",
       "      <th>Question</th>\n",
       "      <th>Mahmud's Note</th>\n",
       "      <th>status</th>\n",
       "      <th>comments</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>1</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Does early administration of neuromuscular blo...</td>\n",
       "      <td>Like</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>2</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>Do patients with severe ARDS being treated wit...</td>\n",
       "      <td>Replace</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>3</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>In patients with moderate to severe ARDS, does...</td>\n",
       "      <td>Maybe this question: In patients with moderate...</td>\n",
       "      <td>fixed</td>\n",
       "      <td></td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>4</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>Do patients with moderate-to-severe ARDS have ...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Wrong concept since PEEP by itself is mandator...</td>\n",
       "      <td>Does the use of neuromuscular blockers in pati...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>ARDS</td>\n",
       "      <td>5</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>Among patients with ALI/ARDS, does a conservat...</td>\n",
       "      <td>Local question (not sure if this is the aim of...</td>\n",
       "      <td>fixed</td>\n",
       "      <td>Check if studies defined conservative by CVP &lt;...</td>\n",
       "      <td></td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  condition  number      docs  \\\n",
       "0      ARDS       1  ACURASYS   \n",
       "1      ARDS       2  ACURASYS   \n",
       "2      ARDS       3      ROSE   \n",
       "3      ARDS       4      ROSE   \n",
       "4      ARDS       5     FACTT   \n",
       "\n",
       "                                            Question  \\\n",
       "0  Does early administration of neuromuscular blo...   \n",
       "1  Do patients with severe ARDS being treated wit...   \n",
       "2  In patients with moderate to severe ARDS, does...   \n",
       "3  Do patients with moderate-to-severe ARDS have ...   \n",
       "4  Among patients with ALI/ARDS, does a conservat...   \n",
       "\n",
       "                                       Mahmud's Note status  \\\n",
       "0                                               Like          \n",
       "1                                            Replace  fixed   \n",
       "2  Maybe this question: In patients with moderate...  fixed   \n",
       "3  Local question (not sure if this is the aim of...  fixed   \n",
       "4  Local question (not sure if this is the aim of...  fixed   \n",
       "\n",
       "                                            comments  \\\n",
       "0                                                      \n",
       "1                                                      \n",
       "2                                                      \n",
       "3  Wrong concept since PEEP by itself is mandator...   \n",
       "4  Check if studies defined conservative by CVP <...   \n",
       "\n",
       "                                                      \n",
       "0                                                     \n",
       "1                                                     \n",
       "2                                                     \n",
       "3  Does the use of neuromuscular blockers in pati...  \n",
       "4                                                     "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Doc No</th>\n",
       "      <th>Confirmed by</th>\n",
       "      <th>Topic</th>\n",
       "      <th>Name</th>\n",
       "      <th>Study Design and Methodology</th>\n",
       "      <th>Study Population</th>\n",
       "      <th>Interventions</th>\n",
       "      <th>Comparator</th>\n",
       "      <th>Outcomes</th>\n",
       "      <th>Strengths and Weaknesses</th>\n",
       "      <th>Key Findings and Conclusion</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Keon</td>\n",
       "      <td>ARDS</td>\n",
       "      <td>ACURASYS</td>\n",
       "      <td>- Multicenter, randomized, double-blind, place...</td>\n",
       "      <td>The study enrolled 340 patients from 20 ICUs i...</td>\n",
       "      <td>- Cisatracurium Group:\\n  - 3-ml rapid IV infu...</td>\n",
       "      <td>- Placebo group receiving identical IV infusio...</td>\n",
       "      <td>Primary Outcome:\\n- 90-day in-hospital mortali...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- Blinded ra...</td>\n",
       "      <td>Key Findings:\\n- Adjusted 90-day survival impr...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Keon</td>\n",
       "      <td>ARDS</td>\n",
       "      <td>ROSE</td>\n",
       "      <td>- Multicenter, unblinded, randomized clinical ...</td>\n",
       "      <td>- Patients with moderate-to-severe ARDS\\n- Cri...</td>\n",
       "      <td>- 48-hour continuous infusion of cisatracurium...</td>\n",
       "      <td>- Usual care approach\\n- No routine neuromuscu...</td>\n",
       "      <td>Primary Outcome:\\n- In-hospital death from any...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- High proto...</td>\n",
       "      <td>Key Findings:\\n No significant difference in 9...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Keon</td>\n",
       "      <td>ARDS</td>\n",
       "      <td>FACTT</td>\n",
       "      <td>- Prospective, randomized clinical trial\\n- Co...</td>\n",
       "      <td>- 1,001 patients with acute lung injury (503 i...</td>\n",
       "      <td>Conservative Strategy:\\n- Lower fluid intake\\n...</td>\n",
       "      <td>The two fluid management strategies were compa...</td>\n",
       "      <td>Primary Outcome:\\n- Death at 60 days\\n\\nSecond...</td>\n",
       "      <td>Strengths:\\n- Randomized design\\n- Multi-cente...</td>\n",
       "      <td>Key Findings:\\n- No significant difference in ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Keon</td>\n",
       "      <td>ARDS</td>\n",
       "      <td>ARDSNet</td>\n",
       "      <td>- Multicenter, randomized controlled trial\\n- ...</td>\n",
       "      <td>- Total Participants: 861 patients\\n- Inclusio...</td>\n",
       "      <td>- Lower Tidal Volume Group:\\n  - Initial tidal...</td>\n",
       "      <td>- Traditional Tidal Volume Group:\\n  - Initial...</td>\n",
       "      <td>Primary Outcomes:\\n- Mortality before hospital...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- Robust ran...</td>\n",
       "      <td>Key Findings:\\n- Mortality reduced by 22% in l...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Keon</td>\n",
       "      <td>ARDS</td>\n",
       "      <td>PROSEVA</td>\n",
       "      <td>- Multicenter, prospective, randomized, contro...</td>\n",
       "      <td>- 466 patients with severe ARDS\\n- Inclusion c...</td>\n",
       "      <td>- Prone group (237 patients):\\n  - Turned to p...</td>\n",
       "      <td>- Supine group (229 patients):\\n  - Remained i...</td>\n",
       "      <td>Primary Outcome:\\n- 28-day mortality\\n\\nSecond...</td>\n",
       "      <td>Strengths:\\n- Multicenter design\\n- Standardiz...</td>\n",
       "      <td>Key Findings:\\n- 28-day mortality: 16.0% (pron...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "  Doc No Confirmed by Topic      Name  \\\n",
       "0      1         Keon  ARDS  ACURASYS   \n",
       "1      2         Keon  ARDS      ROSE   \n",
       "2      3         Keon  ARDS     FACTT   \n",
       "3      4         Keon  ARDS   ARDSNet   \n",
       "4      5         Keon  ARDS   PROSEVA   \n",
       "\n",
       "                        Study Design and Methodology  \\\n",
       "0  - Multicenter, randomized, double-blind, place...   \n",
       "1  - Multicenter, unblinded, randomized clinical ...   \n",
       "2  - Prospective, randomized clinical trial\\n- Co...   \n",
       "3  - Multicenter, randomized controlled trial\\n- ...   \n",
       "4  - Multicenter, prospective, randomized, contro...   \n",
       "\n",
       "                                    Study Population  \\\n",
       "0  The study enrolled 340 patients from 20 ICUs i...   \n",
       "1  - Patients with moderate-to-severe ARDS\\n- Cri...   \n",
       "2  - 1,001 patients with acute lung injury (503 i...   \n",
       "3  - Total Participants: 861 patients\\n- Inclusio...   \n",
       "4  - 466 patients with severe ARDS\\n- Inclusion c...   \n",
       "\n",
       "                                       Interventions  \\\n",
       "0  - Cisatracurium Group:\\n  - 3-ml rapid IV infu...   \n",
       "1  - 48-hour continuous infusion of cisatracurium...   \n",
       "2  Conservative Strategy:\\n- Lower fluid intake\\n...   \n",
       "3  - Lower Tidal Volume Group:\\n  - Initial tidal...   \n",
       "4  - Prone group (237 patients):\\n  - Turned to p...   \n",
       "\n",
       "                                          Comparator  \\\n",
       "0  - Placebo group receiving identical IV infusio...   \n",
       "1  - Usual care approach\\n- No routine neuromuscu...   \n",
       "2  The two fluid management strategies were compa...   \n",
       "3  - Traditional Tidal Volume Group:\\n  - Initial...   \n",
       "4  - Supine group (229 patients):\\n  - Remained i...   \n",
       "\n",
       "                                            Outcomes  \\\n",
       "0  Primary Outcome:\\n- 90-day in-hospital mortali...   \n",
       "1  Primary Outcome:\\n- In-hospital death from any...   \n",
       "2  Primary Outcome:\\n- Death at 60 days\\n\\nSecond...   \n",
       "3  Primary Outcomes:\\n- Mortality before hospital...   \n",
       "4  Primary Outcome:\\n- 28-day mortality\\n\\nSecond...   \n",
       "\n",
       "                            Strengths and Weaknesses  \\\n",
       "0  Strengths:\\n- Multicenter design\\n- Blinded ra...   \n",
       "1  Strengths:\\n- Multicenter design\\n- High proto...   \n",
       "2  Strengths:\\n- Randomized design\\n- Multi-cente...   \n",
       "3  Strengths:\\n- Multicenter design\\n- Robust ran...   \n",
       "4  Strengths:\\n- Multicenter design\\n- Standardiz...   \n",
       "\n",
       "                         Key Findings and Conclusion  \n",
       "0  Key Findings:\\n- Adjusted 90-day survival impr...  \n",
       "1  Key Findings:\\n No significant difference in 9...  \n",
       "2  Key Findings:\\n- No significant difference in ...  \n",
       "3  Key Findings:\\n- Mortality reduced by 22% in l...  \n",
       "4  Key Findings:\\n- 28-day mortality: 16.0% (pron...  "
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "spreadsheet = connect2Googlesheet()\n",
    "\n",
    "# Select the worksheet: relevance\n",
    "Q_worksheet = spreadsheet.get_worksheet(2)\n",
    "# Select the worksheet: revised summary\n",
    "Sum_worksheet = spreadsheet.get_worksheet(6)\n",
    "\n",
    "# Get all records as a list of dictionaries\n",
    "ques_data = Q_worksheet.get_all_records()\n",
    "sum_data = Sum_worksheet.get_all_records()\n",
    "\n",
    "# Convert to Pandas DataFrame\n",
    "df_MedQ = pd.DataFrame(ques_data)\n",
    "df_MedSum = pd.DataFrame(sum_data)\n",
    "\n",
    "# Display the first few rows of both DataFrames\n",
    "display(df_MedQ.head())\n",
    "display(df_MedSum.head())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 2: Build Context before Synthesis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?\n",
      "Found 45 unique relationships:\n",
      "- patients -> blinded_to -> treatment allocation\n",
      "- patients -- blinded_to -- 12-month data collectors\n",
      "- patients -- blinded_to -- study statistician\n",
      "- Liverpool ICU -> data_collected_from -> patients\n",
      "- patients -- data_submitted_to -- Australian & New Zealand Intensive Care Society database\n",
      "- patients -- collected_data -- cardiac arrest patients\n",
      "- patients -- on_call_at -- cardiologist\n",
      "- patients -- treated_in -- cardiac arrest patients\n",
      "- patients -> randomly_assigned_to -> receive haloperidol\n",
      "- patients -> hospitalized_for -> medical and surgical treatments\n",
      "- Fluid and vasopressor management -> is_related_to -> septic shock\n",
      "- acute kidney injury -> has_complication -> septic shock\n",
      "- septic shock -- managed_by -- renal-replacement therapy\n",
      "- clinicians -> diagnosed -> septic shock\n",
      "- septic shock -- challenged_by -- recognizing delirium in the ICU\n",
      "- septic shock -- can_help -- nano strategies\n",
      "- patients -> diagnosed_with -> septic shock\n",
      "- septic shock -- blinded_to -- treatment allocation\n",
      "- septic shock -- data_collected_from -- Liverpool ICU\n",
      "- septic shock -- randomly_assigned_to -- receive haloperidol\n",
      "- Patients -> receives_treatment -> mechanical ventilation\n",
      "- mechanical ventilation -- invited_to -- telephone interview\n",
      "- mechanical ventilation -- transferred_to -- Liverpool Hospital\n",
      "- mechanical ventilation -- undergo -- intubation\n",
      "- mechanical ventilation -- receiving -- drotrecogin alfa\n",
      "- mechanical ventilation -> receiving -> mechanical ventilation\n",
      "- mechanical ventilation -- assigned_to -- hydrocortisone-plus-fludrocortisone therapy\n",
      "- mechanical ventilation -- assigned_to -- placebo\n",
      "- mechanical ventilation -- condition -- receiving mechanical ventilation for less than 12 hours for ARDS\n",
      "- mechanical ventilation -- condition -- undergone intubation\n",
      "- study infusion -> completed_wherever_possible -> 96-hour infusion\n",
      "- study infusion -> extended_through -> day 6\n",
      "- study infusion -> temporarily_interrupted_for -> invasive procedures\n",
      "- study infusion -- associated_with -- serious bleeding events\n",
      "- hydrocortisone -> received_by -> patients\n",
      "- hydrocortisone -- blinded_to -- treatment allocation\n",
      "- hydrocortisone -- data_collected_from -- Liverpool ICU\n",
      "- hydrocortisone -- randomly_assigned_to -- receive haloperidol\n",
      "- hydrocortisone -- hospitalized_for -- medical and surgical treatments\n",
      "- hydrocortisone -- monitored_for -- adverse effects\n",
      "- hydrocortisone -- monitored_for -- delirium status\n",
      "- hydrocortisone -- observed_in -- patient-to-ventilator asynchronies\n",
      "- hydrocortisone -- followed_up -- study personnel\n",
      "- hydrocortisone -- had_primary_site -- lung\n",
      "- Hyperoxemia -> associated_with -> 90-day mortality\n"
     ]
    }
   ],
   "source": [
    "test_question = df_MedQ[\"Question\"][10]\n",
    "context = graph_retriever(graph, test_question, max_depth=2)\n",
    "formatted_relations = parse_relationships(context)\n",
    "print(formatted_relations)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query: Patients with septic shock undergoing mechanical ventilation, did continuous infusion of hydrocortisone result in lower 90-day mortality?\n",
      "Found 45 unique relationships:\n",
      "- patients -> blinded_to -> treatment allocation\n",
      "- patients -- blinded_to -- 12-month data collectors\n",
      "- patients -- blinded_to -- study statistician\n",
      "- Liverpool ICU -> data_collected_from -> patients\n",
      "- patients -- data_submitted_to -- Australian & New Zealand Intensive Care Society database\n",
      "- patients -- collected_data -- cardiac arrest patients\n",
      "- patients -- on_call_at -- cardiologist\n",
      "- patients -- treated_in -- cardiac arrest patients\n",
      "- patients -> randomly_assigned_to -> receive haloperidol\n",
      "- patients -> hospitalized_for -> medical and surgical treatments\n",
      "- Fluid and vasopressor management -> is_related_to -> septic shock\n",
      "- acute kidney injury -> has_complication -> septic shock\n",
      "- septic shock -- managed_by -- renal-replacement therapy\n",
      "- clinicians -> diagnosed -> septic shock\n",
      "- septic shock -- challenged_by -- recognizing delirium in the ICU\n",
      "- septic shock -- can_help -- nano strategies\n",
      "- patients -> diagnosed_with -> septic shock\n",
      "- septic shock -- blinded_to -- treatment allocation\n",
      "- septic shock -- data_collected_from -- Liverpool ICU\n",
      "- septic shock -- randomly_assigned_to -- receive haloperidol\n",
      "- Patients -> receives_treatment -> mechanical ventilation\n",
      "- mechanical ventilation -- invited_to -- telephone interview\n",
      "- mechanical ventilation -- transferred_to -- Liverpool Hospital\n",
      "- mechanical ventilation -- undergo -- intubation\n",
      "- mechanical ventilation -- receiving -- drotrecogin alfa\n",
      "- mechanical ventilation -> receiving -> mechanical ventilation\n",
      "- mechanical ventilation -- assigned_to -- hydrocortisone-plus-fludrocortisone therapy\n",
      "- mechanical ventilation -- assigned_to -- placebo\n",
      "- mechanical ventilation -- condition -- receiving mechanical ventilation for less than 12 hours for ARDS\n",
      "- mechanical ventilation -- condition -- undergone intubation\n",
      "- study infusion -> completed_wherever_possible -> 96-hour infusion\n",
      "- study infusion -> extended_through -> day 6\n",
      "- study infusion -> temporarily_interrupted_for -> invasive procedures\n",
      "- study infusion -- associated_with -- serious bleeding events\n",
      "- hydrocortisone -> received_by -> patients\n",
      "- hydrocortisone -- blinded_to -- treatment allocation\n",
      "- hydrocortisone -- data_collected_from -- Liverpool ICU\n",
      "- hydrocortisone -- randomly_assigned_to -- receive haloperidol\n",
      "- hydrocortisone -- hospitalized_for -- medical and surgical treatments\n",
      "- hydrocortisone -- monitored_for -- adverse effects\n",
      "- hydrocortisone -- monitored_for -- delirium status\n",
      "- hydrocortisone -- observed_in -- patient-to-ventilator asynchronies\n",
      "- hydrocortisone -- followed_up -- study personnel\n",
      "- hydrocortisone -- had_primary_site -- lung\n",
      "- Hyperoxemia -> associated_with -> 90-day mortality\n",
      " And Given the following context in the format [(File Name, Text),...] \n",
      "[('ADRENAL.pdf', 'RENAL) trial to test the hypoth- esis that hydrocortisone results in lower mortality  than placebo among patients with septic shock.17 Methods Trial Design and Oversight Our trial was an investigator-initiated, interna- tional, pragmatic, double-blind, parallel-group,  randomized, controlled trial that compared intra- venous infusions of hydrocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation'), ('ANNANE.pdf', 'CARING FOR THE CRITICALLY ILL PATIENT Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock Djillali Annane, MD, PhD Ve´ronique Se´bille, PhD Claire Charpentier, MD Pierre-Edouard Bollaert, MD, PhD Bruno Franc¸ois, MD Jean-Michel Korach, MD Gilles Capellier, MD'), ('CORTICUS.pdf', 'n engl j med 358;2\\u2003 www.nejm.org\\u2003 january 10, 2008 111 The new england   journal of medicine established in 1812\\t january 10, 2008\\t vol. 358\\u2003 no. 2 Hydrocortisone Therapy for Patients with Septic Shock Charles L. Sprung, M.D., Djillali Annane, M.D., Ph.D., Didier Keh, M.D., Rui'), ('HYPRESS.pdf', ' the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use only in patients with inadequate response to fluid and vasopressor resuscitation.2 However, septic shock rever- sal in the CORTICUS study was reported to be significantly ac- celerated by the administration of hydrocortisone irrespec- tive of the adrenal response to corticotropin. An international consensus statement recommended replacing the terms rela- tive'), ('HYPRESS.pdf', ' 2 randomized clinical trials (RCTs).2 In the study by Annane et al,3 hydro- cortisone improved survival and reversal of septic shock in pa- tients with relative adrenal insufficiency. In the CORTICUS study,4 septic shock was reversed more quickly but mortality was not significantly reduced. The higher risk of mortality and septic shock severity in the study by Annane and colleagues resulted in more restrictive recommendations for hydrocor- tisone use'), ('PLMALDHSS.pdf', 'ORIGINAL ARTICLE Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock Romain Pirracchio, M.D., M.P.H., Ph.D.,1,* Djillali Annane, M.D., Ph.D.,2,3,4,* Andre K. Waschka, Ph.D.,5,6 François Lamontagne, M.D., M.Sc.,7,8'), ('HYPRESS.pdf', 'ortisone to prevent progression to shock in patients with severe sepsis presenting without shock. Methods Study Design The Hydrocortisone for Prevention of Septic Shock (HYPRESS) study is an investigator-initiated, multicenter, placebo- controlled, double-blind RCT supported by the German Fed- eral Ministry of Education and Research. The study was con- ducted in cooperation with the German Sepsis Competence Network (SepNet) and the Clinical Trial Centre Le'), ('APROCCHSS.pdf', ' istry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209.) ABSTR ACT Hydrocortisone plus Fludrocortisone   for Adults with Septic Shock D. Annane, A. Renault, C. Brun‑Buisson, B. Megarbane, J.-P. Quenot, S. Siami,  A. Cariou, X. Forceville, C. Schwebel, C'), ('HYPRESS.pdf', 'Copyright 2016 American Medical Association. All rights reserved. Effect of Hydrocortisone on Development of Shock Among Patients With Severe Sepsis The HYPRESS Randomized Clinical Trial Didier Keh, MD; Evelyn Trips; Gernot Marx, MD; Stefan P. Wirtz, MD; Emad Abduljawwad, MD; Sven Bercker, MD; Holger Bogatsch, MD; Josef Briegel, MD; Christoph Engel, MD'), ('APROCCHSS.pdf', ' hydrocortisone plus fludrocortisone. There  was some imbalance between the two groups  in the distribution of pathogens, with slightly  more viral infections in the hydrocortisone-plus- fludrocortisone group than in the placebo group. The mechanisms by which corticosteroids may  favorably affect the outcome of patients with  septic shock have been detailed recently.7 In  brief, corticosteroids improve cardiovascular func- tion by restoring'), ('APROCCHSS.pdf', 'isone or with drotrecogin alfa (activated), which can modulate  the host response, would improve the clinical outcomes of patients with septic shock. METHODS In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we  evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (ac- tivated), the combination of the three'), ('ADRENAL.pdf', 'rocortisone with matched  placebo in patients with septic shock who were  undergoing mechanical ventilation in an inten- sive care unit (ICU). We conducted the trial in  Australia, the United Kingdom, New Zealand,  Saudi Arabia, and Denmark. The trial management committee designed the  trial. The trial sponsor (the George Institute for  Global Health, Australia) coordinated all the  operational processes and conducted all the sta- tistical analyses. Trained research coordinators'), ('FRESHS.pdf', ' this randomized controlled trial, we evaluated the efﬁcacy of dynamic measures (stroke volume change during passive leg raise) to guide resuscitation and improve patient outcome. RESEARCH QUESTION: Will resuscitation that is guided by dynamic assessments of ﬂuid responsiveness in patients with septic shock improve patient outcomes? STUDY DESIGN AND METHODS: We conducted a prospective, multicenter, randomized clinical trial at 13 hospitals in the United States and United Kingdom. Patients presented'), ('SS3vsSS2.pdf', ' we reanalyzed the results from the ALBIOS study [1] - which in 2014 compared the efficacy of the administration of albumin and crystalloids versus crystalloids alone in patients with septic shock - based on the new definition of septic shock. Our aim was to report differences in the populations classified as Shock-2 or Shock-3, highlighting possible advantages and disadvan- tages of this new definition. Methods This study was a retrospective analysis of data from the ALBIOS'), ('TRISS.pdf', ' Septic Shock (TRISS)  trial to evaluate the effects on mortality of leuko- reduced blood transfusion at a lower versus a  higher hemoglobin threshold among patients  with septic shock who are in the intensive care  unit (ICU). METHODS TRIAL DESIGN AND OVERSIGHT After the approvals from ethics committees and  data-protection agencies were obtained, patients in  32 general ICUs in Denmark, Sweden, Norway, and  Finland underwent screening and randomization'), ('ADRENAL.pdf', '.) abstr act Adjunctive Glucocorticoid Therapy in Patients   with Septic Shock B. Venkatesh, S. Finfer, J. Cohen, D. Rajbhandari, Y. Arabi, R. Bellomo, L. Billot, M. Correa, P. Glass,   M. Harward, C. Joyce, Q. Li, C. McArthur, A. Perner, A. Rhodes, K.'), ('SS3vsSS2.pdf', ' infusion in patients with septic shock. N Engl J Med. 2008; 358:877–87. 13. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:775–87. 14. Rivers E, Nguyen B, Havstad S'), ('SS3vsSS2.pdf', ' in 100 intensive care units in Italy comparing the administration of 20% albumin and crystalloids versus crystalloids alone in patients with severe sepsis or septic shock. We analyzed data from 1741 patients from ALBIOS with serum lactate measurement available at baseline. We compared group size, physiological variables and 90-day mortality between patients defined by Shock-2 and Shock-3 and between the albumin and crystalloid treatment groups. Results: We compared the Shock-2 and the Shock-'), ('SS3vsSS2.pdf', ' degli Studi di Milano, Milan, Italy. 9University of Milan-Bicocca, School of Medicine and Surgery, Monza, Italy. Table 3 Enrolment rate of septic shock patients in recent randomized controlled trials on sepsis Study TRISS [5] SEPSISPAM [6] ProCESS [7] ARISE [8] ALBIOS [1] VASST [12] Patients enrolled (n) 1005 776 13')]\n"
     ]
    }
   ],
   "source": [
    "final_context, filenames = final_context_builder(graph, test_question, method=\"hybrid\")\n",
    "# res = get_firstk_chunks(graph, filenames, firstk=3)\n",
    "print(final_context)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Step 3: Synthesize"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.1 Stance Synthesis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_hy = synthesize_response(\n",
    "    graph,\n",
    "    test_question,\n",
    "    synth_type=\"stance_synthesis\",\n",
    "    method=\"hybrid\",\n",
    "    model=\"gpt-3.5-turbo\",\n",
    ")\n",
    "# response_vec = synthesize_response(\n",
    "#     graph,\n",
    "#     test_question,\n",
    "#     synth_type=\"stance_synthesis\",\n",
    "#     method=\"vector\",\n",
    "#     model=\"gpt-3.5-turbo\",\n",
    "# )\n",
    "# response_gr= synthesize_response(graph, test_question, method=\"graph\", model=\"gpt-3.5-turbo\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hybrid Response:  {\n",
      "  \"PLMALDHSS\": \"Supports\",\n",
      "  \"TRISS\": \"Neutral\",\n",
      "  \"ADRENAL\": \"Against\",\n",
      "  \"APROCCHSS\": \"Supports\",\n",
      "  \"FRESHS\": \"Neutral\",\n",
      "  \"ANNANE\": \"Supports\",\n",
      "  \"SS3vsSS2\": \"Neutral\",\n",
      "  \"HYPRESS\": \"Supports\",\n",
      "  \"CORTICUS\": \"Against\"\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "print(\"Hybrid Response: \", response_hy.choices[0].message.content.strip())\n",
    "# print(\"Vector Response: \", response_vec.choices[0].message.content.strip())\n",
    "# print(\"Graph Response: \", response_gr.choices[0].message.content.strip())"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.2 PICO Synthesis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'\\nresponse_vec = synthesize_response(\\n    graph,\\n    test_question,\\n    synth_type=\"PICO_synthesis\",\\n    method=\"vector\",\\n    model=\"gpt-3.5-turbo\",\\n)\\n'"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "response_hy = synthesize_response(\n",
    "    graph,\n",
    "    test_question,\n",
    "    synth_type=\"PICO_synthesis\",\n",
    "    method=\"hybrid\",\n",
    "    model=\"gpt-3.5-turbo\",\n",
    ")\n",
    "\n",
    "\"\"\"\n",
    "response_vec = synthesize_response(\n",
    "    graph,\n",
    "    test_question,\n",
    "    synth_type=\"PICO_synthesis\",\n",
    "    method=\"vector\",\n",
    "    model=\"gpt-3.5-turbo\",\n",
    ")\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hybrid Response:  Based on the articles provided, the studies can be grouped as follows:\n",
      "\n",
      "### Supporting the Claim:\n",
      "1. **Study 1: PLMALDHSS**\n",
      "   - **Authors:** Romain Pirracchio et al.\n",
      "   - **Year:** 2023\n",
      "   - **Title:** Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock\n",
      "   - **Journal:** NEJM Evidence\n",
      "   - **Research Question:** To evaluate the effect of hydrocortisone infusion on 90-day mortality in patients with septic shock.\n",
      "   - **Study Design:** Meta-analysis of patient-level data from septic shock trials.\n",
      "   - **Population Size:** 528 participants across 17 trials.\n",
      "   - **Intervention:** Hydrocortisone infusion.\n",
      "   - **Primary Outcome:** 90-day mortality was not significantly reduced by hydrocortisone.\n",
      "   - **Key Findings:** Hydrocortisone did not result in lower 90-day mortality compared to placebo.\n",
      "   - **Conclusion:** The study findings do not support the use of hydrocortisone to reduce 90-day mortality in septic shock patients.\n",
      "\n",
      "### Refuting the Claim:\n",
      "2. **Study 2: CORTICUS**\n",
      "   - **Authors:** Charles L. Sprung et al.\n",
      "   - **Year:** 2008\n",
      "   - **Title:** Hydrocortisone Therapy for Patients with Septic Shock\n",
      "   - **Journal:** New England Journal of Medicine\n",
      "   - **Research Question:** To assess the impact of hydrocortisone therapy on mortality in septic shock patients.\n",
      "   - **Study Design:** Randomized, double-blind, placebo-controlled trial.\n",
      "   - **Population Size:** 499 patients with septic shock.\n",
      "   - **Intervention:** Hydrocortisone infusion.\n",
      "   - **Primary Outcome:** No significant difference in mortality between hydrocortisone and placebo groups.\n",
      "   - **Key Findings:** Hydrocortisone did not improve survival or reversal of septic shock.\n",
      "   - **Conclusion:** The study did not find evidence supporting a reduction in mortality with hydrocortisone in septic shock patients.\n",
      "\n",
      "### Equivocal or Inconclusive:\n",
      "3. **Study 3: APROCCHSS**\n",
      "   - This study supports the claim that hydrocortisone plus fludrocortisone reduced 90-day mortality in septic shock patients.\n",
      "\n",
      "In summary, while the meta-analysis and one randomized controlled trial did not find a significant reduction in 90-day mortality with hydrocortisone in septic shock patients, another trial indicated a reduction in mortality with hydrocortisone plus fludrocortisone. The evidence is mixed, with one study refuting the claim, one supporting it, and one providing equivocal results.\n"
     ]
    }
   ],
   "source": [
    "print(\"Hybrid Response: \", response_hy.choices[0].message.content.strip())\n",
    "# print(\"Vector Response: \", response_vec.choices[0].message.content.strip())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_hy = synthesize_response(\n",
    "    graph,\n",
    "    test_question,\n",
    "    synth_type=\"PICO_synthesis\",\n",
    "    method=\"hybrid\",\n",
    "    model=\"gpt-3.5-turbo\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hybrid Response:  ### Supporting the Claim:\n",
      "1. **Study 1: FMWSCPARDS**\n",
      "    - **Authors:** Grissom et al.\n",
      "    - **Year:** 2015\n",
      "    - **Title:** FMWSCPARDS\n",
      "    - **Journal:** Critical Care Medicine\n",
      "    - **Research Question:** Investigate the impact of different fluid management protocols on outcomes in ARDS patients.\n",
      "    - **Type of Study:** Retrospective comparison\n",
      "    - **Methodology:** Compared FACTT Lite, FACTT Conservative, and FACTT Liberal protocols in ARDS patients.\n",
      "    - **Population Size:** 5003 participants across different management protocols.\n",
      "    - **Interventions:** Fluid management by protocol.\n",
      "    - **Outcomes:** Equivalent ventilator-free days in FACTT Lite and FACTT Conservative groups.\n",
      "    - **Key Findings:** FACTT Lite protocol had equivalent ventilator-free days to FACTT Conservative.\n",
      "    - **Conclusion:** FACTT Lite protocol is safe and has similar outcomes to FACTT Conservative.\n",
      "\n",
      "### Supporting the Claim:\n",
      "2. **Study 2: SMDLTSWCI**\n",
      "    - **Authors:** Not mentioned\n",
      "    - **Year:** Not mentioned\n",
      "    - **Title:** SMDLTSWCI\n",
      "    - **Journal:** Not mentioned\n",
      "    - **Research Question:** Compare the effects of different sedatives in critically ill patients.\n",
      "    - **Type of Study:** Randomized controlled study\n",
      "    - **Methodology:** Patients were randomized into different sedative groups.\n",
      "    - **Population Size:** 252 patients\n",
      "    - **Interventions:** Sedation with midazolam alone, dexmedetomidine, or propofol.\n",
      "    - **Outcomes:** Dexmedetomidine group had more ventilator-free days and less delirium.\n",
      "    - **Key Findings:** Dexmedetomidine group had more ventilator-free days and faster extubation.\n",
      "    - **Conclusion:** Dexmedetomidine resulted in more ventilator-free days and less delirium.\n",
      "\n",
      "### Supporting the Claim:\n",
      "3. **Study 3: ACURASYS**\n",
      "    - **Authors:** Papazian et al.\n",
      "    - **Year:** 2010\n",
      "    - **Title:** ACURASYS\n",
      "    - **Journal:** New England Journal of Medicine\n",
      "    - **Research Question:** Evaluate the clinical outcomes of neuromuscular blocking agents in early, severe ARDS.\n",
      "    - **Type of Study:** Multicenter, double-blind trial\n",
      "    - **Methodology:** Randomly assigned patients to receive cisatracurium besylate or placebo.\n",
      "    - **Population Size:** 340 patients\n",
      "    - **Interventions:** Cisatracurium besylate or placebo for 48 hours.\n",
      "    - **Outcomes:** Reduced 90-day in-hospital mortality with cisatracurium.\n",
      "    - **Key Findings:** Cisatracurium group had lower mortality at 90 days.\n",
      "    - **Conclusion:** Cisatracurium reduced mortality in early, severe ARDS patients.\n",
      "\n",
      "### Supporting the Claim:\n",
      "4. **Study 4: TOF-ARDS**\n",
      "    - **Authors:** Not mentioned\n",
      "    - **Year:** Not mentioned\n",
      "    - **Title:** TOF-ARDS\n",
      "    - **Journal:** Not mentioned\n",
      "    - **Research Question:** Evaluate the efficiency of a nurse-directed protocol of NMBA administration based on a train-of-four (TOF) assessment.\n",
      "    - **Type of Study:** Retrospective study\n",
      "    - **Methodology:** Nurse-driven protocol based on TOF monitoring for NMBA administration.\n",
      "    - **Population Size:** 30 patients\n",
      "    - **Interventions:** Cisatracurium administration driven by nurses based on TOF monitoring.\n",
      "    - **Outcomes:** Decreased cisatracurium consumption without affecting neuromuscular block quality.\n",
      "    - **Key Findings:** Nurse-driven TOF-based protocol reduced cisatracurium consumption.\n",
      "    - **Conclusion:** Nurse-driven protocol decreased consumption without affecting neuromuscular block quality.\n",
      "\n",
      "These studies support the claim that early administration of neuromuscular blocking agents can increase ventilator-free days in critically ill patients with ARDS.\n"
     ]
    }
   ],
   "source": [
    "print(\"Hybrid Response: \", response_hy.choices[0].message.content.strip())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "response_hy = synthesize_response(\n",
    "    graph,\n",
    "    test_question,\n",
    "    synth_type=\"PICO_synthesis\",\n",
    "    method=\"hybrid\",\n",
    "    model=\"gpt-4o-mini\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Hybrid Response:  Based on the provided articles, I have categorized the studies according to their findings regarding the claim that early administration of neuromuscular blocking agents (NMBAs) increases ventilator-free days (VFDs):\n",
      "\n",
      "### Supporting the Claim\n",
      "1. **Authors**: Lyu et al.\n",
      "   - **Year**: 2021\n",
      "   - **Title**: The effect of neuromuscular blocking agents uses in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials.\n",
      "   - **Journal**: Minerva Anestesiologica\n",
      "   - **Research Question**: Does the early administration of NMBAs improve ventilator-free days in patients with moderate to severe ARDS?\n",
      "   - **Type of Study**: Meta-analysis of randomized controlled trials.\n",
      "   - **Methodology**: Reviewed multiple RCTs comparing early NMBA use versus control in ARDS patients, focusing on VFDs.\n",
      "   - **Population Size**: Data from numerous trials with a total of 1,953 patients.\n",
      "   - **Key Findings**: Early NMBA infusion was associated with increased ventilator-free days and reduced ICU mortality (RR: 0.69; 95% CI: 0.55-0.88).\n",
      "   - **Strengths**: Comprehensive analysis of multiple studies, robust statistical methods.\n",
      "   - **Weaknesses**: Variability in study protocols and definitions of early administration.\n",
      "   - **Conclusion**: Early NMBA use is beneficial for increasing VFDs in ARDS patients.\n",
      "\n",
      "2. **Authors**: Papazian et al.\n",
      "   - **Year**: 2010\n",
      "   - **Title**: Neuromuscular blocking agents in early acute respiratory distress syndrome.\n",
      "   - **Journal**: New England Journal of Medicine\n",
      "   - **Research Question**: Do NMBAs improve outcomes in early severe ARDS?\n",
      "   - **Type of Study**: Multicenter, double-blind RCT.\n",
      "   - **Methodology**: 340 patients with early severe ARDS were randomized to receive either NMBA (cisatracurium) or placebo.\n",
      "   - **Population Size**: 340 patients.\n",
      "   - **Key Findings**: The NMBA group exhibited greater VFDs and improved oxygenation compared to placebo, with a hazard ratio for mortality at 90 days being 0.68 (significant).\n",
      "   - **Strengths**: Large sample size, rigorous design.\n",
      "   - **Weaknesses**: Potential for bias in patient selection.\n",
      "   - **Conclusion**: Supports the claim that NMBA administration increases VFDs.\n",
      "\n",
      "### Refuting the Claim\n",
      "1. **Authors**: Murthy et al.\n",
      "   - **Year**: 2022\n",
      "   - **Title**: Early use of neuromuscular blocking agents in COVID-19 ARDS.\n",
      "   - **Journal**: Critical Care Medicine\n",
      "   - **Research Question**: Does early NMBA administration affect VFDs in COVID-19 patients with ARDS?\n",
      "   - **Type of Study**: Propensity score-matched cohort study.\n",
      "   - **Methodology**: Analyzed data from 1953 patients to compare NMBA treatment versus control.\n",
      "   - **Population Size**: 1953 patients.\n",
      "   - **Key Findings**: No significant increase in VFDs (16 vs. 25 days in NMBA vs. control, respectively, p = 0.12).\n",
      "   - **Strengths**: Broad patient sample, well-matched groups.\n",
      "   - **Weaknesses**: Retrospective design may limit causality.\n",
      "   - **Conclusion**: Early NMBA use did not significantly increase VFDs.\n",
      "\n",
      "### Equivocal or Inconclusive\n",
      "1. **Authors**: Jones et al.\n",
      "   - **Year**: 2016\n",
      "   - **Title**: High-Dose Dexmedetomidine for Sedation in the Intensive Care Unit: An Evaluation of Clinical Efficacy and Safety.\n",
      "   - **Journal**: Annals of Pharmacotherapy\n",
      "   - **Research Question**: What is the effect of high-dose dexmedetomidine on VFDs in ICU patients?\n",
      "   - **Type of Study**: Retrospective study.\n",
      "   - **Methodology**: Compared high and low doses of dexmedetomidine in sedated ICU patients.\n",
      "   - **Population Size**: 133 patients.\n",
      "   - **Key Findings**: No clear impact on VFDs; however, sedation quality improved.\n",
      "   - **Strengths**: Relevant to sedation practices in mechanically ventilated patients.\n",
      "   - **Weaknesses**: Small sample size, retrospective nature.\n",
      "   - **Conclusion**: Findings are inconclusive regarding NMBA effects on VFDs.\n",
      "\n",
      "### Summary\n",
      "Overall, the evidence is mixed regarding the claim that early administration of neuromuscular blocking agents increases ventilator-free days. While some studies support the claim, others show no significant effect, particularly in specific populations such as COVID-19 patients. Further research is recommended to clarify these findings and establish clear guidelines for NMBA use in ARDS treatment.\n"
     ]
    }
   ],
   "source": [
    "print(\"Hybrid Response: \", response_hy.choices[0].message.content.strip())"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
